Atorvastatin causes regression of endometriotic implants in a rat model

Reprod Biomed Online. 2010 Feb;20(2):291-9. doi: 10.1016/j.rbmo.2009.11.004. Epub 2009 Nov 26.


Endometriotic implants were induced surgically in female Wistar albino rats, which were randomly divided into three groups. The rats in group I (n=10) and group II (n=9) were given 2.5 mg/kg/day intraperitoneal and oral atorvastatin, respectively, for 28 days. Group III (n=9) was given no medication (control). The mean volume and weight of explants in group I were significantly lower (both P < 0.05) compared with group III. Histopathological score of the implants was significantly lower in groups I and II, when compared with group III (P < 0.01 and P < 0.05, respectively). There were significant reductions in explant concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 in group I (P < 0.01 and P < 0.001, respectively) and group II (both P < 0.01) compared with group III while staining due to tissue inhibitor of metalloproteinase 2 was significantly higher in group I (P < 0.01) and group II (P < 0.01) compared with group III. Moreover, explant concentration of superoxide dismutase was significantly increased in groups I and II compared with group III (both P < 0.05). In conclusion, atorvastatin causes significant regression of endometriotic implants in rats. Moreover, intraperitoneal atorvastatin seems to be more effective than oral atorvastatin.

MeSH terms

  • Animals
  • Antioxidants / adverse effects
  • Antioxidants / therapeutic use*
  • Atorvastatin
  • Disease Models, Animal
  • Endometriosis / drug therapy*
  • Endometriosis / pathology
  • Endometrium / drug effects
  • Endometrium / pathology
  • Female
  • Heptanoic Acids / adverse effects
  • Heptanoic Acids / therapeutic use*
  • Pyrroles / adverse effects
  • Pyrroles / therapeutic use*
  • Rats
  • Rats, Wistar


  • Antioxidants
  • Heptanoic Acids
  • Pyrroles
  • Atorvastatin